Navigation Links
Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
Date:7/29/2011

DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

"Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis.  After taking the drug for approximately ten months, Bo's parents noticed unusual bruising covering his body while on a family vacation," says drug defect attorney Andy Vickery.

"Bo immediately underwent various tests and was diagnosed with T cell acute lymphoblastic leukemia; a dangerous side effect Abbott Laboratories knew could affect Humira users but failed to warn them about."  

Vickery says because of the Humira-induced leukemia, Bo now must continue to undergo intense treatment that could potentially cause long-term and serious side effects, and could possibly develop secondary cancers as he matures.

Prior to the launch of Humira in 2003, other similar drugs had been linked to lymphoma and other forms of cancer, and clinical trial data suggested that there was a very significant epidemiological "signal" about the risk.  Once Humira was launched, many adverse event reports were submitted regarding cancers, however Abbott did nothing to warn about this.  Bo was diagnosed with Leukemia on January 8, 2009, over seven months after the FDA said that physicians and patients should be warned about this side effect, and nearly ten months before a Black Box warning was finally issued regarding Humira-induced leukemia in pediatric and adolescent patients.

Humira (Adalimumab) is a class of biologic drugs known as TNF (Tumor Necrosis Factor) blockers. It works by blocking naturally occurring proteins that cause inflammation.  However, research has shown that taking drugs like Humira can compromise the immune system and can have a devastating and even deadly effect resulting in serious infections, cancer, allergic reactions, Hepatitis B virus reactivation, nervous system problems, heart failure, blood issues and certain immune reactions. Humira is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, crohn's disease, and plaque psoriasis. With 2010 sales of $6.5 billion, Humira is Abbott's flagship drug.

Perdue Kidd & Vickery is a national law firm of Board Certified Personal Injury Trial Lawyers.  The law practice is based in Houston, TX.   Further information is available at http://www.HumiraJustice.com. View an educational video about Humira fungal infections.


'/>"/>
SOURCE Perdue Kidd & Vickery
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Endo International plc (NASDAQ: ENDP ) ... , President, U.S. Branded Pharmaceuticals, has decided to ... of a successor. Mr. Lortie joined Endo in ... responsibility for all strategic, commercial and operational functions, ... commercial operations, managed markets, manufacturing, supply chain and ...
(Date:5/5/2016)... Cayman , May 5, 2016 Progra ... trial of Oxitec , s mosquito ... Aedes aegypti by 96 %   ... announced a new plan to fight wild Aedes aegypti, the dangerous ... diseases on the island of Grand Cayman .  MRCU, a ...
(Date:5/5/2016)... 5, 2016 Research and Markets has announced ... Top 5 EU Markets"  report to their offering.  ,     (Logo: ... information on the current Positron Emission Tomography (PET) scanner and ... EU), which includes France , ... Spain and the United Kingdom ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... This Mother’s Day kicks off the start of an ... National Women’s Health Week takes place May 8-May 14. , Throughout the celebration, ... empower women to make their health a top priority. Women everywhere are being encouraged ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... ... 05, 2016 , ... Pivot Point Consulting achieved ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, ... consulting services for electronic health record (EHR) solutions from Epic Systems Corporation ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit their products ... “tobacco product,” apply to all vaping products that entered the market since February ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TLC Laser Eye ... Diego, California. The laser eye center will now be called “Gordon Schanzlin New Vision ... staff will remain at the full-service facility to ensure that patients continue to receive ...
Breaking Medicine News(10 mins):